kelfiprim profile

kelfiprim: combination of trimethoprim & sulfametopyrazine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	64934
MeSH ID	M0087922

Synonym
sulfalene + trimethoprim
benzenesulfonamide, 4-amino-n-(3-methoxypyrazinyl)-, mixt. with 5-((3,4,5-trimethoxyphenyl)methyl)-2,4-pyrimidinediamine
kelfiprim
trimed
50933-06-7
DTXSID50198966
4-amino-n-(3-methoxypyrazin-2-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine

Research Excerpts

Overview

Kelfiprim (KP) is a new bactericidal agent containing trimethoprim (T) and sulfametopyrazine (S), a long-acting sulfonamide (ratio 5:4)

Excerpt	Reference	Relevance
"Kelfiprim (KP) is a new bactericidal agent containing trimethoprim (T) and sulfametopyrazine (S), a long-acting sulfonamide (ratio 5:4). "	( Kelfiprim versus co-trimoxazole in recurrent and persistent urinary tract infections: multicenter double-blind trial. Cantaluppi, A; Chiarini, C; Graziani, G; Limido, D; Locatelli, F; Marai, P; Piaia, F; Pincella, G; Ponticelli, C; Zucchelli, P, 1987)	3.16

Pharmacokinetics

Excerpt	Reference	Relevance
" Multiple samples were collected over 9 days and the following pharmacokinetic parameters were calculated: total area under the plasma level curve, slow disposition rate constant beta and the corresponding t1/2 beta, plasma clearance and the apparent volume of distribution."	( Pharmacokinetic study of the new sulfamethopyrazine-trimethoprim combination (kelfiprim) in renal insufficiency. Cantaluppi, A; Grasso, S; Graziani, G; Meinardi, G; Piaia, F; Ponticelli, C; Tamassia, V, 1984)	0.5

Compound-Compound Interactions

Excerpt	Reference	Relevance
"A double-blind, multi-centre trial was carried out in 72 patients with acute or chronic infections of the lower respiratory tract to compare the efficacy and tolerance of a sulfamethopyrazine (200 mg)/trimethoprim (250 mg) combination with that of the established combination co-trimoxazole (400 mg sulphamethoxazole plus 80 mg trimethoprim)."	( A multi-centre trial comparing a sulfamethopyrazine/trimethoprim combination with co-trimoxazole in respiratory tract infections. Bagnato, A; Colombo, F; Colombo, ML; Dei, D; Donno, L; Ginesu, F; Ortu, AR; Peona, V, 1984)	0.27

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	18 (94.74)	18.7374
1990's	1 (5.26)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	8 (42.11%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	1 (5.26%)	4.05%
Observational	0 (0.00%)	0.25%
Other	10 (52.63%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
sulfamethoxazole Sulfamethoxazole: A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208). sulfamethoxazole : An isoxazole (1,2-oxazole) compound having a methyl substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 3-position.	5.44	4	4	isoxazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial agent; antiinfective agent; antimicrobial agent; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; epitope; P450 inhibitor; xenobiotic
trimethoprim Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.	7.48	19	8	aminopyrimidine; methoxybenzenes	antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic
ampicillin Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.	4.31	2	2	beta-lactam antibiotic; penicillin allergen; penicillin	antibacterial drug
sulfalene Sulfalene: Long-acting plasma-bound sulfonamide used for respiratory and urinary tract infections and also for malaria.	7.48	19	8	pyrazines; sulfonamide antibiotic; sulfonamide
amoxicillin Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.	3.35	1	1	penicillin allergen; penicillin	antibacterial drug
trimethoprim, sulfamethoxazole drug combination Trimethoprim, Sulfamethoxazole Drug Combination: A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.. co-trimoxazole : A two-component mixture comprising trimethoprim and sulfamethoxazole.	5.44	4	4
tetracycline Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.	3.35	1	1

Condition	Relationship Strength	Studies	Trials
Urinary Tract Infections Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.	5.65	7	3
Bronchial Pneumonia [description not available]	3.35	1	1
Experimental Lung Inflammation Inflammation of any part, segment or lobe, of the lung parenchyma.	3.35	1	1
Infections, Respiratory [description not available]	4.96	3	3
Bronchitis Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI.	3.35	1	1
Pneumonia Infection of the lung often accompanied by inflammation.	3.35	1	1
Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.	9.96	3	3
Recrudescence [description not available]	4.04	3	1
Bacterial Disease [description not available]	2.88	4	0
Acute Bacterial Prostatitis [description not available]	2.37	2	0
Bacterial Infections Infections by bacteria, general or unspecified.	2.88	4	0
Cystitis Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.	2.37	2	0
Prostatitis Infiltration of inflammatory cells into the parenchyma of PROSTATE. The subtypes are classified by their varied laboratory analysis, clinical presentation and response to treatment.	2.37	2	0
Sinus Infections [description not available]	4.6	3	2
Acute Disease Disease having a short and relatively severe course.	4.82	4	2
Sinusitis Inflammation of the NASAL MUCOSA in one or more of the PARANASAL SINUSES.	4.6	3	2
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	1.96	1	0
Cronobacter Infections [description not available]	1.96	1	0
Enterobacteriaceae Infections Infections with bacteria of the family ENTEROBACTERIACEAE.	1.96	1	0
Chronic Illness [description not available]	2.37	2	0
Middle Ear Inflammation [description not available]	1.95	1	0
ENT Diseases [description not available]	1.95	1	0
Nasal Catarrh [description not available]	1.95	1	0
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	2.37	2	0
Otitis Media Inflammation of the MIDDLE EAR including the AUDITORY OSSICLES and the EUSTACHIAN TUBE.	1.95	1	0
Rhinitis Inflammation of the NASAL MUCOSA, the mucous membrane lining the NASAL CAVITIES.	1.95	1	0
Tonsillitis Inflammation of the tonsils, especially the PALATINE TONSILS but the ADENOIDS (pharyngeal tonsils) and lingual tonsils may also be involved. Tonsillitis usually is caused by bacterial infection. Tonsillitis may be acute, chronic, or recurrent.	1.95	1	0
Agranulocytosis A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).	1.97	1	0
Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.	1.97	1	0
E coli Infections [description not available]	1.96	1	0
Infections, Klebsiella [description not available]	1.96	1	0
Escherichia coli Infections Infections with bacteria of the species ESCHERICHIA COLI.	1.96	1	0
Klebsiella Infections Infections with bacteria of the genus KLEBSIELLA.	1.96	1	0

kelfiprim

Description

Cross-References

Synonyms (7)

Research Excerpts

Overview

Pharmacokinetics

Compound-Compound Interactions

Research

Studies (19)

Market Indicators

Research Demand Index: 18.56

Study Types

kelfiprim

Description

Cross-References

Synonyms (7)

Research Excerpts

Overview

Pharmacokinetics

Compound-Compound Interactions

Research

Studies (19)

Market Indicators

Research Demand Index: 18.56

Study Types

Related Drugs (7)

Related Conditions (33)